In BC, miR-223-3p may suppress BC development by targeting oncogenic transcripts, including epithelial cell transforming 2 (ECT2), Profilin 2 (PFN2) and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) as examples, or act as a onco-miR by enhancing cell proliferation, migration, invasion, and EMT through Hippo/Yap1or Notch signalling pathways as examples [45]. This evidence concerns the gene NLRP3 and breast cancer.